title: Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
abstract: Ovarian endocrine function was assessed in 88 women using NORPLANT subdermal implants during different periods of use and in a control group of 15 women using non-hormonal contraception. Blood samples for estradiol (E2) and progesterone (P) assays were obtained twice a week for five consecutive weeks. Three distinct E2 patterns were observed: one was characterized by fluctuating levels within a normal range (20 to 400 pg/ml), a second pattern corresponded to continuous low E2 levels (below 75 pg/ml in the 10 samples) and the third was characterized by high broad estradiol peaks reaching over 400 pg/ml. The proportion of sampling runs characterized by normal fluctuating levels increased from 38% in the first two years of use to 80% during the fifth year of use. Low E2 profile was only observed during the first two years of use (27%) and in only 1 case at the beginning of the third year of use (5%). The percentage of cycles with high broad estradiol peaks remained between 20-40% without a clear tendency to change in either direction with duration of use. Thirty-three percent of the observed sampling runs had luteal activity (P above 3 ng/ml). The proportion of runs with luteal activity increased from 14% during the first two years of use to 40% during the third and fourth, and 60% during the fifth year of use. All control subjects had luteal activity. The mean highest progesterone level was lower in the NORPLANT runs (8.7 +/- 3.9 ng/ml) as compared to the controls (11.3 +/- 3.8 ng/ml). NORPLANT sampling runs with luteal activity had normal fluctuating E2 levels with only one exception. However, not all cycles with normal E2 levels showed luteal activity. On the other hand, all runs with low E2 levels or high broad E2 peaks were without luteal activity. In summary, women using continuous low-dose levonorgestrel contraception through NORPLANT subdermal implants, have a variable degree of ovarian activity as compared with the more complete depression of ovarian function observed among pill or injectables' users. Ovarian activity becomes closer to normal during the third through fifth year of use.
authors.affiliation: CINSERHA--PROFAMILIA, Santo Domingo, Dominican Republic.
authors.forename: V
authors.initials: V
authors.lastname: Brache
authors.forename: F
authors.initials: F
authors.lastname: Alvarez-Sanchez
authors.forename: A
authors.initials: A
authors.lastname: Faundes
authors.forename: A S
authors.initials: AS
authors.lastname: Tejada
authors.forename: L
authors.initials: L
authors.lastname: Cochon
mesh_terms: D003271:Contraceptive Agents, Female / Q000494:pharmacology*; D004343:Drug Implants; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D016912:Levonorgestrel; D008137:Longitudinal Studies; D008183:Luteal Phase / Q000187:drug effects; D009644:Norgestrel / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects* / Q000502:physiology; D011374:Progesterone / Q000097:blood
chemical_list: D003271:Contraceptive Agents, Female; D004343:Drug Implants; D009644:Norgestrel; D011374:Progesterone; D004958:Estradiol; D016912:Levonorgestrel